Myocardial Dysfunction in Primary Mitral Regurgitation


Por: Anand, V, Bonow, RO, Nishimura, RA, Delgado, V, Cavalcante, JL, Puthumana, JJ, Narang, A, Hung, JW, Thomas, JD, Ranard, LS and Rigolin, VH

Publicada: 1 feb 2026 Ahead of Print: 1 dic 2025
Resumen:
This narrative review describes current guidelines for intervention in severe primary mitral regurgitation and explores an approach that incorporates additional injury assessment, novel imaging markers, and biomarkers to optimize surgical timing. ImportancePrimary mitral regurgitation (MR) is a prevalent valvular lesion. Current American College of Cardiology/American Heart Association guidelines include class I recommendations for intervention for severe primary MR at the onset of symptoms, significant left ventricular (LV) enlargement (end-systolic dimension >= 40 mm), or dysfunction (ejection fraction <= 60%), with a class IIA recommendation for mitral valve repair when performed at an experienced surgical center. Recent data suggest a survival penalty when waiting for class I surgical guideline indications, and novel markers of decompensation are under investigation.ObservationsComprehensive assessment of MR severity using echocardiography is critical, and when warranted, cardiac magnetic resonance (CMR) is complementary. Assessment of LV size and function, as well as serial changes in both, is crucial for determining timing of surgery. New-onset atrial fibrillation, left atrial enlargement, pulmonary hypertension, and exercise-induced changes in LV function should also be considered in borderline scenarios. The roles of LV volumes, global longitudinal strain, CMR-derived measures of myocardial dysfunction, and cardiac biomarkers are worthy of further investigation regarding consideration for early surgical intervention.Conclusions and RelevanceA more refined approach incorporating assessment of extravalvular cardiac injury, novel imaging markers, and biomarkers is needed to optimize surgical timing in primary MR. Further research is warranted to validate these emerging parameters and refine guidelines to improve patient outcomes.

Filiaciones:
Anand, V:
 Mayo Clin, Dept Cardiovasc Med, Rochester, MN USA

Bonow, RO:
 Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL USA

Nishimura, RA:
 Mayo Clin, Dept Cardiovasc Med, Rochester, MN USA

:
 Univ Hosp Germans Trias & Pujol, Dept Cardiol, Badalona, Spain

Cavalcante, JL:
 Allina Hlth Minneapolis Heart Inst, Minneapolis, MN USA

Puthumana, JJ:
 Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL USA

Narang, A:
 Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL USA

Hung, JW:
 Massachusetts Gen Hosp, Dept Cardiovasc Med, Boston, MA USA

Thomas, JD:
 Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL USA

Ranard, LS:
 Columbia Univ, Dept Cardiovasc Med, Med Ctr, New York, NY USA

Rigolin, VH:
 Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL USA
ISSN: 23806583





JAMA Cardiology
Editorial
American Medical Association, 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA, Estados Unidos America
Tipo de documento: Review
Volumen: 11 Número: 2
Páginas: 199-207
WOS Id: 001642649400001
ID de PubMed: 41405892

MÉTRICAS